Commentary - Journal of Infectious Diseases and Medical Microbiology (2025) Volume 9, Issue 1

Antibody Therapy: A Revolutionary Approach in Treating Diseases

G.Tarique^*

Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates

*Corresponding Author:

G.Tarique
Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates
E-mail:gtarique@iul.ac.in

Received: : 01-Jan-2025, Manuscript No. AAJIDMM - 25-161883; Editor assigned: 05-Jan-2025, PreQC No. AAJIDMM - 25-161883 (PQ); Reviewed: 19-Jan-2025, QC No. AAJIDMM - 25-161883; Revised:22-Jan-2025, Manuscript No. AAJIDMM - 25-161883 (R); Published:29-Jan-2025, DOI:10.35841/10.35841/ aajidmm-9.1.248

Citation: Citation: Tarique G. Antibody Therapy: A Revolutionary Approach in Treating Diseases. J Infect Dis Med Microbiol. 2025; 9(1):248

Introduction

Antibody therapy, also known as monoclonal antibody (mAb) therapy, has emerged as one of the most promising and innovative approaches in modern medicine. It involves the use of antibodies, which are specialized proteins produced by the immune system to identify and neutralize foreign substances, such as pathogens or cancer cells. [

Over the past few decades, monoclonal antibody therapy has revolutionized the treatment of a wide range of diseases, from cancer and autoimmune disorders to infectious diseases and viral infections. By harnessing the power of antibodies, scientists have been able to design therapies that specifically target and bind to molecules involved in disease processes, either neutralizing harmful pathogens or blocking disease promoting pathways. In this article, we explore the science behind antibody therapy, its applications in various fields of medicine, and the future of this therapeutic approach. [2, 3].

Antibodies are proteins produced by the immune system to recognize and neutralize foreign invaders like viruses, bacteria, and toxins. They work by binding to specific antigens on the surface of pathogens or diseased cells, marking them for destruction by other immune cells or neutralizing their harmful effects [4].

Monoclonal antibodies (mAbs) are laboratorymade antibodies that are engineered to bind to specific targets in the body, often with high precision. The process of creating monoclonal antibodies involves a combination of genetic engineering and hybridoma technology. In this process, a mouse (or other animal) is immunized with a target antigen, and immune cells (B cells) that produce antibodies against the antigen are collected. [5].

These cells are then fused with myeloma cells (cancer cells that can replicate indefinitely), creating a hybrid cell called a hybridoma. Hybridomas can be cultured to produce large quantities of the desired antibody, which can then be purified and used for therapeutic purposes. Over the years, advances in biotechnology have allowed for the creation of fully human monoclonal antibodies, which are less likely to be recognized as foreign by the human immune system, thus reducing the risk of immune reactions. [6, 7].

Antibody therapies have a wide range of applications across various fields of medicine. Below are some of the most notable areas where monoclonal antibodies have made a significant impact. Cancer immunotherapy is one of the most rapidly advancing fields in medicine, and monoclonal antibodies are at the forefront of this revolution. [8].

By targeting specific molecules on the surface of cancer cells or immune cells, monoclonal antibodies can block cancer cell growth, enhance the immune system’s ability to attack tumors, and improve patient outcomes. A monoclonal antibody used to treat HER2-positive breast cancer by binding to the HER2 receptor on cancer cells, blocking their growth signals. Used to treat non-Hodgkin lymphoma and chronic lymphocytic leukaemia by targeting the CD20 antigen on B cells, leading to their destruction [9].

While antibody therapies have revolutionized medicine, there are still several challenges to overcome: Monoclonal antibodies are complex to produce, and their high cost can limit accessibility, particularly in low- and middle-income countries. The development of more cost-effective production methods and greater availability of biosimilar (non-branded versions of monoclonal antibodies) may help address this issue. Although monoclonal antibodies are generally well tolerated, some patients may develop infusion reactions or immune responses to the therapy. These reactions can range from mild flu-like symptoms to more severe responses like anaphylaxis or cytokine release syndrome. In cancer therapy, some tumors may develop resistance to monoclonal antibodies by altering their target antigens or activating compensatory signaling pathways. Ongoing research is focused on overcoming resistance mechanisms and improving the efficacy of monoclonal antibody treatments. [10].

conclusion

Antibody therapy has become a cornerstone of modern medicine, offering highly targeted and effective treatment options for a wide range of diseases, including cancers, autoimmune disorders, infections, and more. The ability to design antibodies that specifically target disease-causing molecules has revolutionized our approach to treatment, improving patient outcomes and quality of life. As research and technology continue to advance, the potential for monoclonal antibody therapy to treat additional diseases and overcome current limitations is vast. With continued innovation, antibody therapies are poised to play an even greater role in shaping the future of personalized and precision medicine, offering hope for patients worldwide.

References

1. Schlaberg R, Chiu CY, Miller S, et al. Validation of metagenomic next-generation sequencing tests for universal pathogen detection. Arch Pathol Lab Med. 2017;141(6):776-86.

Indexed at, Google Scholar, Cross Ref

2. Fu Y, Chen Q, Xiong M, et al. Clinical performance of nanopore targeted sequencing for diagnosing infectious diseases. Microbiol Spectr. 2022;10(2):e00270-22.

Indexed at, Google Scholar, Cross Ref

3. Zamani M, Furst AL, Klapperich CM. Strategies for engineering affordable technologies for point-of-care diagnostics of infectious diseases. Acc Chem Res. 2021;54(20):3772-9.

Indexed at, Google Scholar, Cross Ref

4. Diaferio L, Giovannini M, Clark E, et al. Protocols for drug allergy desensitization in children. Expert Rev Clin Immunol. 2020;16(1):91-100.

Indexed at, Google Scholar, Cross Ref

5. de Brito Pinto TK, da Cunha-Oliveira AC, Sales-Moioli AI, et al. Clinical protocols and treatment guidelines for the management of maternal and congenital syphilis in brazil and portugal: analysis and comparisons: a narrative review. Int J Environ Res Public Health. 2022;19(17):10513.

Indexed at, Google Scholar, Cross Ref 

6. Masterson L, Moualed D, Masood A, et al. De?escalation treatment protocols for human papillomavirus?associated oropharyngeal squamous cell carcinoma. Cochrane Database Syst Rev. 2014(2).

Indexed at, Google Scholar, Cross Ref

7. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev. 2010;23(3):550-76.

Indexed at, Google Scholar, Cross Ref

8. King DP, Madi M, Mioulet V, et al. New technologies to diagnose and monitor infectious diseases of livestock: challenges for sub-Saharan Africa: proceeding. Onderstepoort J Vet Res. 2012;79(2):1-6.

Indexed at, Google Scholar, Cross Ref

9. Shirlaw PJ, Chikte U, MacPhail L, et al. Oral and dental care and treatment protocols for the management of HIV?infected patients. Oral Dis. 2002;8:136-43.

Indexed at, Google Scholar, Cross Ref

10. Lagier JC, Aubry C, Delord M, et al. From expert protocols to standardized management of infectious diseases. Clin Infect Dis. 2017;65(suppl_1):S12-9.

Indexed at, Google Scholar, Cross Ref